Taiwan Visual Prosthesis Market Size & Outlook, 2025-2033
Taiwan Visual Prosthesis Market Insights
- According to Reed Intelligence analysis, the Taiwan Visual Prosthesis Market size was USD 3.42 Million in 2024 and is projected to reach USD 9.59 Million by 2033.
- The Taiwan market is projected to grow at a CAGR of 12.04% between 2026 and 2033.
- By segment, Retina Implant Alpha AMS emerged as the largest By Product Type in terms of market size in 2024.
- Others is anticipated to remain the most attractive By Product Type segment, recording the fastest growth during the forecast period.
Source: RI Analysis Company Publications, Primary Interviews.
Other Key Findings
- In 2024, Taiwan accounted for 1.02% of the global Visual Prosthesis Market size.
- By 2033, United States is expected to lead the global Visual Prosthesis Market in terms of market size.
- Within Asia Pacific, China is projected to dominate the regional Visual Prosthesis Market size by 2033.
- Australia is identified as the fastest-growing market in Asia Pacific, anticipated to reach USD 9.75 Million by 2033.
Report Summary
| Report Scope | Details |
|---|---|
| Base Year for Study | 2024 |
| Study Period | 2021-2033 |
| Historical Period | 2021-2023 |
| Forecast Period | 2025-2033 |
| Market Size In 2024 | USD 3.42 Million |
| Market Size In 2033 | USD 9.59 Million |
| Largest segment | Retina Implant Alpha AMS |
| Units | Revenue in USD Million |
| CAGR | 12.04% (2025-2033) |
| Segmnetation Covered | |
| By Product Type |
|
| By Indication |
|
| By End-User |
|
| Report Coverage | Revenue Forecast, Competitive Landscape, Growth Factors, Environment & Regulatory Landscape and Trends |
Taiwan Visual Prosthesis Market By Product Type 2025-2033 (USD Million)
| By Product Type | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Retina Implant Alpha AMS | XX.x | XX.x | XX.x | 1.64 | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Implantable Miniature Telescope | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Argus II | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Others | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Total | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
Source: RI Analysis Company Publications, Primary Interviews.
Taiwan Visual Prosthesis Market By Indication 2025-2033 (USD Million)
| By Indication | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Age-Related Macular Degeneration (AMD) | XX.x | XX.x | XX.x | 1.79 | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Retinitis Pimentos (RP) | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Other Retinal Degenerative Diseases | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Total | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
Source: RI Analysis Company Publications, Primary Interviews.
Taiwan Visual Prosthesis Market By End-User 2025-2033 (USD Million)
| By End-User | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Speciality eye clinics | XX.x | XX.x | XX.x | 1.39 | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Eye hospitals | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Eye care centres | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Others | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Total | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
Source: RI Analysis Company Publications, Primary Interviews.
